 SpringWorks Therapeutics Inc NASDAQ: SWTX announced an update on the previously reported interim data from the first 20 adult patients enrolled in Phase 2b ReNeu trial evaluating mirdametinib for NF1-associated plexiform neurofibromas NF1-PN, Data were presented at the 2021 Childrens Tumor Foundation NF Conference. 